Core Viewpoint - Yiling Pharmaceutical has been selected for the Xinhua News Agency Brand Project, which aims to support the development of national enterprises and enhance Chinese brand building through a comprehensive service platform [1][2]. Group 1: Company Overview - Yiling Pharmaceutical, founded in 1992, focuses on technological innovation as the foundation of its business, aiming to transform innovation into brand success [1]. - The company has established a new discipline in traditional Chinese medicine, the theory of meridian diseases, and has published educational materials that are taught in over 40 higher education institutions globally [1][2]. Group 2: Innovation Focus - The company emphasizes three main areas of innovation: theoretical innovation, technological innovation, and open innovation [2]. - Yiling Pharmaceutical has created a national key laboratory for the transformation of meridian disease theory, conducting research on cardiovascular diseases, respiratory diseases, and aging, which has led to the development of 17 innovative patented traditional Chinese medicines [2]. - The Tongxinluo capsule, developed under the guidance of meridian theory, has been clinically proven to reduce the risk of death from acute myocardial infarction by 30% and the annual recurrence risk by 74%, marking a significant breakthrough for traditional Chinese medicine on the global stage [2]. Group 3: Achievements and Recognition - Over the past 30 years, Yiling Pharmaceutical has received six major scientific achievement awards, including the National Science and Technology Progress Award First Class, and has filled multiple industry gaps [2]. - The company has been recognized as one of the top 100 Chinese brand value enterprises, demonstrating the effectiveness of its brand building through "technological innovation + quality assurance + social responsibility" [2]. Group 4: Future Outlook - Yiling Pharmaceutical plans to leverage its selection for the Xinhua News Agency Brand Project to further promote and innovate traditional Chinese medicine, accelerating the internationalization of its brand and culture [2].

Group 1 - The third China International Supply Chain Promotion Expo (Chain Expo) was held from July 16 to 20 in Beijing, showcasing vibrant cooperation between domestic and foreign enterprises in the health and wellness sector [1] - Starbucks China participated for the third consecutive time, forming a carbon reduction alliance with strategic partners and showcasing its ready-to-drink business for the first time at the expo [2] - L'Oréal, the only foreign beauty company at the expo, highlighted its innovative capabilities in the daily chemical and beauty industry, with 62% of its sales coming from products manufactured in China [2][4] Group 2 - Tsingtao Group presented its complete supply chain system at the expo, celebrating the 50th anniversary of China-Thailand diplomatic relations and emphasizing the importance of China in the global supply chain [3] - The CEO of Tsingtao Group expressed confidence in China's economic prospects and the unique advantages of its supply chain, viewing the expo as a valuable opportunity for international collaboration [3] - Traditional Chinese medicine companies showcased innovative health experiences, with Yiling Pharmaceutical presenting a series of innovative traditional Chinese medicines based on the theory of collateral diseases [4] Group 3 - China Resources Group exhibited its comprehensive health industry ecosystem, focusing on the theme of "Guarding Health Across the Chain, Creating a Better Life" through multimedia interactions and core product displays [5] - Guangdong province, as the guest province, showcased 64 enterprises, including China Resources Group and TCL, highlighting the integration of traditional medicine and modern technology [5] - The health life chain exhibition area demonstrated China's core position in the global health industry chain and the innovative fusion of traditional medicine with modern technology [5]

Core Viewpoint - Vikon Pharmaceutical has been recognized for its innovative patent in traditional Chinese medicine, showcasing its technological strength and market potential in the healthcare industry [4]. Group 1: Patent and Recognition - Vikon Pharmaceutical's patent for "a sustained-release heat-resistant pill matrix and the silver-yellow pill containing this matrix" won the "25th China Patent Excellent Award," indicating national-level recognition of the company's technological capabilities in modernizing traditional Chinese medicine [4]. - The core product, Silver Yellow Pill, has demonstrated significant advantages in treating acute and chronic throat inflammation, tonsillitis, and upper respiratory infections, leading to its recognition in various industry awards [2][4]. Group 2: Research and Development - The company has established multiple research platforms, including provincial high-tech enterprise R&D centers and expert workstations, enhancing its competitiveness in pharmaceutical research and development [2]. - The completion of Phase II clinical trials for Silver Yellow Pill targeting recurrent oral ulcers indicates ongoing efforts to expand its application scenarios, potentially driving future market growth [2]. Group 3: Market Strategy and Growth - Vikon Pharmaceutical is leveraging the advantages of its production location in Longquan, known for its "Chinese Ganoderma first town," to create a pollution-free and additive-free product line, enhancing its market appeal [3]. - The application of low-temperature physical ultra-micro wall-breaking technology has improved the bioavailability of its Ganoderma spore powder products, contributing to a competitive edge in the market [3]. - The company is actively engaging with capital markets, as evidenced by a recent visit from a securities firm, indicating potential for further collaboration in capital operations and industrial upgrades [3].

京东健康作为行业领先的医疗健康服务企业，拥有庞大的用户基础，并构建了完善的医疗健康服务体 系，包括在线问诊、药品配送、健康管理等一站式服务。这些优势将有助于显著提升八珍益母片新品的 市场覆盖率和用户触达率。 京东健康医药业务部相关负责人表示，京东健康一直致力于为消费者提供优质的医药健康产品和服务， 八珍益母片作为妇科领域的经典中成药，赢得了广泛的市场认可。相信通过双方的携手合作，将帮助更 多女性用户便捷获取这一优质产品，让传统中医药更好地满足现代女性的健康需求。 编辑：王菁 此次在京东健康线上首发的千金八珍益母片新品，精选当归、党参、川芎、熟地黄、童子益母草等九味 道地药材，配合超微粉碎等现代技术，确保药材活性成分保留率超90%，生物利用度提升68%。同时， 通过专利工艺处理，使芍药苷等有效成分含量达到国家药典标准的2.3倍，显著提升了药物疗效。 临床试验数据显示，针对月经量少（＜20ml／周期）、经血色淡、经期延长（＞7天）伴面色萎黄、乏 力懒言等典型气血两虚证候，千金八珍益母片新规产品总有效率达91.2%。此外，产品不仅适用于产 后、更年期、术后等气血亏虚状态，还为职场白领、健身达人、节食减肥人群提供亚健 ...

Group 1 - Traditional Chinese medicine (TCM) is increasingly integrated into daily life, supported by favorable national policies promoting innovation and development in the sector [1][4] - The Luofu Mountain area, known for its rich history in TCM, hosts over 1,240 species of medicinal plants and has been a cultural hub for TCM for centuries [2][4] - The Luofu Mountain Forum and the Guangdong-Hong Kong-Macao Greater Bay Area TCM Culture Festival gathered over a hundred experts to discuss the inheritance and development of TCM culture [4][6] Group 2 - The forum featured multiple sessions focusing on TCM innovation, cultural transmission, and industry collaboration, highlighting the importance of these areas for future growth [6] - The Luofu Mountain National Medicine has evolved into a modern high-tech pharmaceutical enterprise, ranking among the top 20 TCM companies in Guangdong Province by 2024 [8] - A strategic cooperation agreement was signed between Luofu Mountain National Medicine and Runkang Pharmaceutical to develop a comprehensive health industry park and promote TCM culture [8] Group 3 - The National Health Commission and TCM Bureau have emphasized the integration of TCM culture into daily life, promoting the supply of TCM products and enhancing public health [9] - Runkang is focusing on the standardization of TCM dietary therapy products, developing over 50 local specialty health products to promote TCM culture and expand market reach [9] - The initiative aims to lead a new trend in health preservation and support high-quality development of TCM, while also exploring international markets [9]

Core Viewpoint - In 2024, Yiling Pharmaceutical (002603) faced competitive pressure in the pharmaceutical industry and adhered to a strategy focused on "standardization, professionalism, health, sustainability, and leapfrogging," aiming for brand success, scale formation, goal achievement, and profit creation [1] Financial Performance - In 2024, Yiling Pharmaceutical reported revenue of 6.513 billion yuan, a year-on-year decrease of 36.88%, and a net profit attributable to shareholders of -0.725 billion yuan, down 153.57% [2] - The decline in performance was attributed to the expiration of certain respiratory products, leading to reduced sales and inventory impairment losses, alongside rising raw material costs and sustained high R&D investments [2] - Despite the net loss, operating cash flow significantly improved, reaching 0.611 billion yuan, a year-on-year increase of 293%, with Q4 cash flow alone at 0.288 billion yuan, up over 26 times [2] - Accounts receivable decreased significantly, with a reduction of 1.176 billion yuan, a drop of 50%, and total liabilities decreased to 3.117 billion yuan, down 24.24 billion yuan or 43.75%, resulting in a debt-to-asset ratio decline of nearly 10 percentage points to 23.4% [2] R&D Investment - Yiling Pharmaceutical maintained a strong focus on R&D, with expenses reaching 0.908 billion yuan in 2024, accounting for 13.94% of revenue, reinforcing its leadership in traditional Chinese medicine innovation [3] - The company developed 17 innovative traditional Chinese medicines targeting eight major clinical disease systems, achieving industry leadership in cardiovascular and respiratory disease treatments [3] - New drug approvals included a treatment for allergic rhinitis and a new drug for gallbladder inflammation, with several patented traditional medicines included in the new medical insurance directory [3] Market Expansion and Strategic Initiatives - Yiling Pharmaceutical has registered products in over 50 countries and regions, actively entering the biopharmaceutical and health sectors, with recent approval for a breast cancer treatment [4] - Continuous R&D investment is expected to enhance product offerings and market share, while the transformation of technological innovations will improve product structure and competitiveness [4] - The company’s strategic focus on R&D and market trends positions it for greater growth in the pharmaceutical market [4] 2025 Outlook - In Q1 2025, Yiling Pharmaceutical reported revenue of 2.358 billion yuan and a net profit of 0.326 billion yuan, reflecting a year-on-year increase of 7.25% [5] - The company’s operating cash flow reached 0.34 billion yuan, nearly doubling year-on-year, with gross margin increasing by 2.34 percentage points to 53.82% [5] - The company aims to enhance its innovation capabilities, accelerate drug development, and implement a brand strategy while optimizing operational management and cost control [6]

Group 1: Financial Performance - The company's revenue for 2024 is reported at 4,753,532,923.52, while the net profit is 880,530,741.58, with a significant increase in profit in Q4 to 158,509,540.77 [2][20] - In 2024, the company's labor costs decreased to 32,043,251.93 from 40,118,945.11 in 2023, indicating effective cost control measures [2][3] - The company experienced a slight decline in revenue but a rise in net profit, suggesting a sustainable growth trend despite industry challenges [2][4] Group 2: Accounts Receivable Management - The company has established a customer credit rating system and dedicated accounts receivable management roles to ensure timely collection of receivables [2][3] - A significant portion of accounts receivable is within one year, indicating a focus on short-term collections [2] Group 3: Research and Development - The company received a subsidy of 3,500,000.00 for "Innovative Application R&D," emphasizing its commitment to R&D in traditional Chinese medicine [6][13] - New product developments, including the transformation of a patented material into industrial production, are underway, with market potential being explored [4][6] Group 4: Strategic Initiatives - The company plans to launch a modern Chinese medicine intelligent manufacturing project, with construction expected to start in 2025 and a three-year timeline for completion [10][24] - Future strategies include enhancing internal management, optimizing investment structures, and focusing on sustainable development [6][14] Group 5: Market Outlook - The pharmaceutical manufacturing industry is expected to grow due to increasing market demand driven by population growth and advancements in medical technology [8][18] - The company remains optimistic about its market position and the overall industry outlook, despite recent challenges faced by competitors [8][25]